Llorente/Sandvig publish potential biomarkers for prostate cancer
Llorente (left) and Sandvig
Alicia Llorente and Kirsten Sandvig, Department of Biochemistry, Institute for Cancer Research and Centre for Cancer Biomedicine, have recently published in Molecular and Cellular Proteomics (impact factor 8.4) a proteomic analysis of microvesicles released from a human prostate cancer cell line. Most of the 266 proteins identified have previously been reported to be present in vesicles released from other cell types, but several proteins seem to be specific for prostate cancer cells. Since microvesicles can reach biological fluids, these proteins are thus potentially useful as new non invasive biomarkers for detection, diagnosis and/or prognosis of prostate cancer.
From major journals, first or last author from the Institute for Cancer Research
Eggebø MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, Yang W, Laos M, Blaas I, Rustad EH, Bollineni RC, Delic-Sarac M, Lund-Johansen F, Nielsen MM, Olweus J(2025) TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors Nat Immunol(in press) DOI 10.1038/s41590-025-02252-1, PubMed 40866620
Ullern A, Holm K, Andresen NK, Røssevold AH, Bang C, Naume B, Hov JR, Kyte JA(2025) Gut microbiota diversity is prognostic in metastatic hormone receptor-positive breast cancer patients receiving chemotherapy and immunotherapy Mol Oncol(in press) DOI 10.1002/1878-0261.70117, PubMed 40852937
Foldvari Z, Brennan MS, Titov A, Jacobsen SEW, Olweus J(2025) Targeting the roots of myeloid malignancies with T cell receptors Nat Rev Cancer(in press) DOI 10.1038/s41568-025-00857-0, PubMed 40841587
Sagini K, Selvarajah M, Romero S, Bassols-Citores E, Martin-Gracia B, Ramirez-Garrastacho M, Rise F, Endzeliņš E, Sadovska L, Skorinkina D, Boguševiča M, Cešeiko R, Čampa M, Klavina A, Linē A, Llorente A(2025) The Redox Enzyme Thioredoxin Is Increased in Plasma Extracellular Vesicles From Endurance-Trained Females in Response to Acute Exercise FASEB J, 39(16), e70927 DOI 10.1096/fj.202500678R, PubMed 40810354
Eggebø MS, Heinzelbecker J, Palashati H, Chandler N, Tran TT, Li Y, Yang W, Laos M, Blaas I, Rustad EH, Bollineni RC, Delic-Sarac M, Lund-Johansen F, Nielsen MM, Olweus J(2025) TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors Nat Immunol(in press) DOI 10.1038/s41590-025-02252-1, PubMed 40866620
Mauthe M, van de Beek N, Mari M, Korsten G, Nobari P, Castelino KB, de Mattos EP, Ouhida I, Dijkstra JL, Schipper-Krom S, de la Ballina LR, Mueller MR, Simonsen A, Hipp MS, Kapitein LC, Kampinga HH, Reggiori F(2025) A chaperone-proteasome-based fragmentation machinery is essential for aggrephagy Nat Cell Biol(in press) DOI 10.1038/s41556-025-01747-1, PubMed 40866512